Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 12:28 pm Purchase | 2026-03-31 | 13G | NRX PHARMACEUTICALS INC NE NRXP | Anson Funds Management LP | 1,736,737 4.900% | 131,762 (+8.21%) | Filing History |
| 2025-08-21 06:42 am Purchase | 2025-08-18 | 13G | NRX PHARMACEUTICALS INC NE NRXP | B Group Inc. | 3,000,000 12.620% | 3,000,000 (New Position) | Filing History |
| 2025-08-14 9:53 pm Purchase | 2025-06-30 | 13G | NRX PHARMACEUTICALS INC NE NRXP | Anson Funds Management LP | 1,604,975 9.300% | 425,914 (+36.12%) | Filing History |
| 2025-05-15 5:15 pm Purchase | 2025-03-31 | 13G | NRX PHARMACEUTICALS INC NE NRXP | Anson Funds Management LP | 1,179,061 7.000% | 1,179,061 (New Position) | Filing History |
| 2022-09-13 4:47 pm Purchase | 2022-07-01 | 13D | NRX PHARMACEUTICALS INC NRXP | Javitt Daniel C. | 987,290 14.600% | 987,290 (New Position) | Filing History |
| 2022-06-17 5:00 pm Unchanged | 2022-06-13 | 13D | NRX PHARMACEUTICALS INC NRXP | Javitt Jonathan C | 1,486,833 22.300% | 0 (Unchanged) | Filing History |
| 2022-06-03 3:59 pm Sale | 2022-06-01 | 13D | NRX PHARMACEUTICALS INC NRXP | Javitt Jonathan C | 1,486,833 22.300% | -1,305,168 (-46.75%) | Filing History |
| 2021-11-02 4:02 pm Sale | 2021-07-16 | 13D | NRX PHARMACEUTICALS INC NRXP | Javitt Jonathan C | 2,792,001 48.190% | -86,918 (-3.02%) | Filing History |